Using AI to diagnose melanoma in young patients
AI-MEL: Image Analysis and Machine Learning for Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
German Cancer Research Center · NCT06621810
This study is testing if artificial intelligence can help doctors better identify melanoma in children and young adults by looking at skin images.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | German Cancer Research Center (other) |
| Locations | 3 sites (Tübingen and 2 other locations) |
| Trial ID | NCT06621810 on ClinicalTrials.gov |
What this trial studies
This study aims to develop artificial intelligence algorithms to help distinguish melanoma from benign skin lesions in children, adolescents, and young adults. It focuses on creating algorithms based on dermatoscopic and histological images to enhance skin cancer screening and assist pathologists. The study will utilize data collected during routine clinical practice, requiring no additional time commitment from participants. Explainability methods will also be implemented to improve user understanding and trust in the AI systems.
Who should consider this trial
Good fit: Ideal candidates for this study are children, adolescents, and young adults under the age of 30 who are undergoing routine skin assessments.
Not a fit: Patients without a melanoma or nevus diagnosis or those with insufficient image quality will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of melanoma in younger patients, potentially improving outcomes.
How similar studies have performed: Other studies have shown promise in using AI for melanoma detection, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Exclusion Criteria: * Patients without a melanoma or nevus diagnosis * images with insufficient image quality
Where this trial is running
Tübingen and 2 other locations
- University of Tübingen — Tübingen, Germany (COMPLETED)
- University of Florence — Florence, Italy (COMPLETED)
- Hospital Clínic de Barcelona — Barcelona, Spain (RECRUITING)
Study contacts
- Principal investigator: Titus J Brinker, PD Dr. med — German Cancer Research Center
- Study coordinator: Titus J Brinker, PD Dr. med
- Email: titus.brinker@nct-heidelberg.de
- Phone: +49 15175084347
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma, Artificial Intelligence, Pediatric Cancer, melanoma, AI, pediatric, image analysis, Children Adolescence Young Adults